CRDL — Cardiol Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- CA$203.61m
- CA$176.05m
Annual balance sheet for Cardiol Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 83.9 | 59.5 | 34.9 | 30.6 | 21.4 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.407 | 0.48 | 0.28 | 0.362 | 0.226 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 87.1 | 61.4 | 36.2 | 31.7 | 23.5 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.356 | 0.296 | 0.337 | 0.196 | 0.118 |
| Net Intangible Assets | |||||
| Total Assets | 87.9 | 62 | 36.7 | 31.9 | 23.6 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11.6 | 9.8 | 8.3 | 7.01 | 5.66 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 11.6 | 9.83 | 8.45 | 7.14 | 5.74 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 76.2 | 52.2 | 28.2 | 24.7 | 17.9 |
| Total Liabilities & Shareholders' Equity | 87.9 | 62 | 36.7 | 31.9 | 23.6 |
| Total Common Shares Outstanding |